Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

Fulgent Genetics, Inc.

FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.
Median progression-free survival 6.7 months; median duration of response 7.4 months.
One-year overall survival rate 63.4% in target population.
Phase 3 study is planned based on these results.
Data cutoff April 16, 2026; presentation at ASCO 2026 Rapid Oral Abstract Session.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.